{"schemaVersion":"ready-scan.discovery-surface.v1","id":"urn:readyscan:corpus:buyer-question:nanjing-pathgene-biotech-co-ltd-q141514913-answer-26a2f40607f00fc51d2e","key":"buyer_question:nanjing-pathgene-biotech-co-ltd-q141514913-answer-26a2f40607f00fc51d2e","kind":"buyer_question","slug":"nanjing-pathgene-biotech-co-ltd-q141514913-answer-26a2f40607f00fc51d2e","canonicalUrl":"https://directory.readyscan.ai/corpus/buyer-question/nanjing-pathgene-biotech-co-ltd-q141514913-answer-26a2f40607f00fc51d2e","machineUrl":"https://directory.readyscan.ai/discovery/corpus/buyer-question/nanjing-pathgene-biotech-co-ltd-q141514913-answer-26a2f40607f00fc51d2e.json","datePublished":"2026-10-27","dateModified":"2026-10-27","materialFingerprint":"fnv1a64:6c1de565aca573b7","membershipFingerprint":"fnv1a64:0709d0dd63f074c2","relatedEntitySlugs":["nanjing-pathgene-biotech-co-ltd-q141514913"],"relatedSurfaceKeys":["buyer_question:nanjing-pathgene-biotech-co-ltd-q141514913-answer-0812e1c86c3aad2fb31a","buyer_question:nanjing-pathgene-biotech-co-ltd-q141514913-answer-21c02993e347ca4a9d67","buyer_question:nanjing-pathgene-biotech-co-ltd-q141514913-answer-527345b3fe2bbe0a426a","buyer_question:nanjing-pathgene-biotech-co-ltd-q141514913-answer-737cf86260e757bfd28c","buyer_question:nanjing-pathgene-biotech-co-ltd-q141514913-answer-73af3e5a3f613b1c2a5a","buyer_question:nanjing-pathgene-biotech-co-ltd-q141514913-answer-7930914df0576f743fdb","buyer_question:nanjing-pathgene-biotech-co-ltd-q141514913-answer-7c63492e62cb71a0dbf6","buyer_question:nanjing-pathgene-biotech-co-ltd-q141514913-answer-82b1e43a194d43081d35","buyer_question:nanjing-pathgene-biotech-co-ltd-q141514913-answer-94582e2137455cbb1120","buyer_question:nanjing-pathgene-biotech-co-ltd-q141514913-answer-a99030c2ed41762791de","buyer_question:nanjing-pathgene-biotech-co-ltd-q141514913-answer-b4b1e9076ac894b4c897","buyer_question:nanjing-pathgene-biotech-co-ltd-q141514913-answer-b88f0fd11e30942edd99","buyer_question:nanjing-pathgene-biotech-co-ltd-q141514913-answer-f35c9bd4e076ef962020","evidence:nanjing-pathgene-biotech-co-ltd-q141514913"],"sourceIds":["ready-scan-subjects"],"provenance":[{"snapshotId":"nanjing-pathgene-biotech-co-ltd-q141514913-content-09dd39e670dac074-snapshot","sourceId":"ready-scan-subjects","sourceRecordId":"Q141514913","sourceRevisionId":"Q141514913:content:575cbcd3d7d39cc5","sourceContentHash":"fnv1a64:a8b06c8a0631c331","recordRevisionId":"Q141514913:content:575cbcd3d7d39cc5","recordContentHash":"fnv1a64:796cced7ac58665a","sourceCanonicalUrl":"https://pathgenebio.com/","sourceModifiedAt":"2026-10-27T03:32:47.772Z","observedOn":"2026-10-27","permission":{"basis":"public_information","evidenceUrl":"https://pathgenebio.com/"},"attributionUrl":"https://pathgenebio.com/"}],"quality":{"method":"same_kind_unique_trigram_floor","minimumUniqueTrigramRatio":0.3,"status":"passed"},"title":"Is low-endotoxin NAD+ the same as sterile or injectable-grade NAD+?","summary":"Cited source answers across 1 active corpus record.","question":"Is low-endotoxin NAD+ the same as sterile or injectable-grade NAD+?","answers":[{"entitySlug":"nanjing-pathgene-biotech-co-ltd-q141514913","entityName":"Nanjing PathGene Biotech Co., Ltd.","answer":"“No. The third-party endotoxin result of ≤0.1 EU/mg applies only to the tested batch. It does not by itself demonstrate sterility, pyrogen-free status, injectable suitability or finished-product regulatory compliance. The buyer must validate the final intended use.”","sourceUrls":["https://pathgenebio.com/en/products/nad-53-84-9"]}]}